Impaired speed-dependent modulation of the gait pattern in multiple sclerosis

ConclusionThe incapacity to modify specific elements of the walking pattern according to walking speed contributes to gait dysfunction in people with MS limiting activities of daily living. Gait modulation may serve as sensitive marker of walking function in MS.Trial registrationClinicaltrials.gov, NCT01576354; first posted April 12, 2012.
Source: Journal of Neurology - Category: Neurology Source Type: research

Related Links:

Publication date: Available online 3 July 2020Source: Multiple Sclerosis and Related DisordersAuthor(s): Rasha M. Fahmi, Mahamoud El Sayed El Ebeary, Esraa M. Abd-Elrasheed, Takwa H.M. Elkhatib
Source: Multiple Sclerosis and Related Disorders - Category: Neurology Source Type: research
CONCLUSIONS: No association between BMI and processing speed was found among PwMS regardless of demographic or disease-specific patient characteristics. PMID: 32619239 [PubMed - as supplied by publisher]
Source: Archives of Clinical Neuropsychology - Category: Psychiatry & Psychology Authors: Tags: Arch Clin Neuropsychol Source Type: research
The gait stability indices can potentially be used outside of a laboratory setting to measure walking characteristics related to fall history and disability level in people with multiple sclerosis.
Source: Clinical Biomechanics - Category: Orthopaedics Authors: Source Type: research
AbstractBackgroundTreatments may become redundant in older patients with multiple sclerosis (MS). Our aim was to explore whether stopping treatments might be possible in patients aged over 50 with disease inactivity.MethodsPatients over 50 were included from the population-based MS Lorraine registry if they had a relapsing –remitting course at onset and had experienced no relapse for ≥ 3 years. Patients who stopped treatments were defined as “stoppers”, and the others as “stayers”. The outcomes were the time to first relapse, to first disability progression, and to the oc...
Source: Journal of Neurology - Category: Neurology Source Type: research
Henze Santoyo-Medina Feys Goal setting is a core component of physical therapy in multiple sclerosis (MS). It is unknown whether and to what extent goals are set at different levels of the International Classification of Functioning, Disability and Health (ICF), and whether, and to which, standardized outcome measures are used in real life for evaluation at the different ICF levels. Our aim was to describe the real-world use of goal setting and outcome measures in Europe. An online cross-sectional survey, completed by 212 physical therapists (PTs) specialized in MS from 26 European countries, was conducted. Dif...
Source: International Journal of Environmental Research and Public Health - Category: Environmental Health Authors: Tags: Article Source Type: research
Conclusions This analysis supports the association between CSF CHI3L1 levels and neurologic disability according to EDSS scores in patients with PPMS. Other chitinase-like proteins such as CHI3L2 may also be involved. Classification of evidence This study provides Class II evidence that CSF CHI3L1 is associated with neurologic disability in patients with PPMS.
Source: Neurology Neuroimmunology and Neuroinflammation - Category: Neurology Authors: Tags: Cerebrospinal Fluid, Multiple sclerosis, Cohort studies, Natural history studies (prognosis), Risk factors in epidemiology Article Source Type: research
Our objective was to develop a novel approach to generate individual maps of white matter (WM) innate immune cell activation using 18F-DPA-714 translocator protein PET and to explore the relationship between these maps and individual trajectories of worsening disability in patients with multiple sclerosis (MS). Methods: Patients with MS (n = 37), whose trajectories of worsening disability over the 2 y preceding study entry were calculated, and healthy controls (n = 19) underwent MRI and 18F-DPA-714 PET. A threshold for significant activation of 18F-DPA-714 binding was calculated with a voxelwise randomized permutation-base...
Source: Journal of Nuclear Medicine - Category: Nuclear Medicine Authors: Tags: Clinical Source Type: research
CONCLUSIONS: TBO shows correlation with the conditions which were revealed to be associated with iron accumulation in thebrain of MS patients in theliterature. Therefore, we concluded that TBO and its severity in DGM may represent iron accumulation in MS brains. ADVANCES IN KNOWLEDGE: TBO effect as a frequent imaging finding in dailypractice, may be used as predictor of the disease course of multiple sclerosis due to possible effects of iron accumulation in brain and thereby, may be useful in modifying treatment strategies. PMID: 32614611 [PubMed - as supplied by publisher]
Source: The British Journal of Radiology - Category: Radiology Authors: Tags: Br J Radiol Source Type: research
Cerebellar damage occurs frequently in multiple sclerosis (MS) patients, with a wide exhibition of symptoms particularly as impairments of balance and gait. Recent studies implementing new postprocessing magnetic resonance imaging (MRI) techniques showed how cerebellar subregional atrophy provides an explanation of disability in MS. The aim of this work was to evaluate the relationship between quantitative measures of physical disability, cerebellar subregional atrophy, and cerebellar peduncle disruption. Forty-nine MS patients and 32 healthy subjects as controls (HS) underwent a 3-Tesla MRI including 3D T1-weighted and di...
Source: Frontiers in Neurology - Category: Neurology Source Type: research
             Basel, 29 June 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that Japan ’s Ministry of Health, Labour and Welfare (MHLW) has approved ENSPRYNG® (satralizumab) for the prevention of relapses of neuromyelitis optica spectrum disorder (NMOSD), including NMO, for aquaporin-4 antibody (AQP4-IgG) seropositive adults and children. ENSPRYNG demonstrated robust efficacy and s ignificantly reduced the risk of relapse across a broad NMOSD patient population in two pivotal Phase III studies, as a monotherapy and as an add-on therapy to ...
Source: Roche Media News - Category: Pharmaceuticals Source Type: news
More News: Brain | Disability | Multiple Sclerosis | Neurology